Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial. - Jean-Sébastien Hulot, Joe-Elie Salem, Alban Redheuil, Shaida Varnous, Patrick Jourdain, Damien Logeart, Stéphane N. Hatem, Richard Isnard, Claude Le Feuvre, Pascal Leprince, Nadjib Hammoudi, François M. Lemoine, David Klatzmann, Eric Vicaut, Michel Komajda - Dissemin

Language
Login

Published in

Wiley, European Journal of Heart Failure, 11(19), p. 1534-1541, 2017

DOI: 10.1002/ejhf.826

Links

ORCID
Wiley | PDF

Tools

Export citation

Search in Google Scholar

Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial.

Journal article published in 2017 by Jean-Sébastien Hulot, Joe-Elie Salem, Alban Redheuil, Shaida Varnous, Patrick Jourdain, Damien Logeart, Stéphane N. Hatem, Richard Isnard, Claude Le Feuvre, Pascal Leprince, Nadjib Hammoudi, François M. Lemoine, David Klatzmann, Eric Vicaut, Michel Komajda and other authors.

This paper is made freely available by the publisher.

This paper is made freely available by the publisher.

Full text: Download

Green circle

Preprint: archiving allowed

Upload

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO